An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels.
Sulpiride is a new and chemically different neuroleptic. In a study of 16 severely ill schizophrenic patients, this compound displayed definite evidence of antipsychotic activity while producing few adverse reactions. The relative absence of extrapyramidal side effects may indicate that sulpride has a low potential for producing tardive dyskinesia. Two patients who did not develop significant increases in prolactin levels did show a definite therapeutic response to sulpiride. Thus it appears that central dopaminergic blockade in the hypothalamic area is not a prerequisite for antipsychotic activity.
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects; D008297:Male; D011388:Prolactin / Q000097:blood*; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy*; D013469:Sulpiride / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D013469:Sulpiride; D011388:Prolactin; D013006:Growth Hormone